Join the PANTS Study!

Inclusion of patients receiving Biosimilar Infliximab - Remsima™ & Inflectra™

Dr Tariq Ahmad

The latest version of the PANTS protocol allows the inclusion of Crohn's disease patients receiving Biosimilar Infliximab. Specifically this allows

  • Inclusion of anti-TNF naive Crohn's disease patients starting Remsima™ or Inflectra™
  • Existing PANTS study participants receiving RemicadeTM to switch to Remsima™ or Inflectra™

The PANTS study is a prospective uncontrolled cohort study investigating primary non-response, loss of response and adverse drug reactions to Infliximab and Adalimumab in patients with severe active luminal Crohn's disease. The study started in March 2013 and to date 1200 patients aged over 6 years have been recruited from 118 UK hospitals. The collection of clinical data is aligned and shared with the Royal College of Physicians UK IBD Biologics Audit (and in due course with the UK IBD registry), and individual patient laboratory data is released on the web portal.

Biosimilar Infliximab became available in the UK in February 2015 offering significant savings to the National Health Service. Extensive non-clinical and clinical data have shown comparability with the reference product, Remicade™. However the clinical data to date has emerged from the use of Biosimilar Infliximab in studies of patients with Ankylosing Spondylitis and Rheumatoid Arthritis. The PANTS study will report the initial UK experience of Biosimilar Infliximab in Crohn's disease, providing important post-authorisation data on efficacy (at week 14, 30 and 54), safety (to 3 years) and pharmacokinetics. We aim to include 225 patients treated with Biosimilar Infliximab as first-line anti-TNF treatment and 100 PANTS "switchers" over the next 12 months. Please do consider recruiting your patients to the PANTS study.

For further information please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 01392 406850

Recruitment for PPALM Study

Refer your patients with radiotherapy-induced bleeding

This randomised, double-blind, placebo-controlled, NIHR-approved trial is recruiting patients with new-onset rectal bleeding affecting quality of life and due to radiation-induced telangiectasia who are free of other abnormal GI symptoms.

For further details or to arrange referral contact:

Jennifer Matthews, trial coordinator
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: 0207 352 8171 ext. 1515

Recruitment deadline: January 2016

Paediatric European Digestive Diseases Clinical Research Network – PEDDCReN

PEDDCReN was an exciting new initiative with the key aim of forming a clinical trials network to study (and ultimately provide) effective medicines for paediatric patients in the speciality of Gastroenterology, Hepatology and Nutrition. It was established with the support of LINK funding from the UEG and was led by the BSG in collaboration with various European societies and ENPR-EMA (The European Network of Paediatric Research at the European Medicines Agency). The project supported both industry and non-industry investigators in running high quality multi-centre clinical trials. The final report has now been published.

HCV clinical trial and tissue biobank

Professor Will Irving ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ) is chief investigator for an observational study (UKCRN 11582) of 10,000 patients with laboratory evidence of HCV infection, either past or current. Information about the study is included as 'Study of the Month' in the October NIHR Specialty Group newsletter. The aim is to develop a biobank, analyse the contribution of a range of host and viral factors to disease outcome, and determine the clinical utility of routine IL-28B genotyping in the management of HCV-infected patients in the UK. For further information please contact Professor Irving.


IBD Nixon Twin and Multiplex Registry

UK gastroenterologists are invited to refer concordant and discordant twin pairs, as well as families where three or more first degree relatives have an IBD diagnosis, to the twin/multiplex registry. We will collect epidemiological data and invite members to donate to a biobank. This will become a powerful research resource that will be available for research collaborations in the future. Further information about how to refer twins or families is available from Hannah Gordon, Senior Clinical Research Fellow (Gastroenterology), IBD Nixon TAM Registry Co-Investigator, Chelsea and Westminster Hospital, This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Page 1 of 3